Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Pauline Ho et al.|The Lancet|2021Cited by 315
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trialFelice Rivellese, Raquel Celis, Anna E. A. Surace et al.|Nature Medicine|2022Cited by 277
Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoidBernard Lauwerys, Frédéric Houssiau, É. Hachulla et al.|Arthritis & Rheumatism|2012Cited by 168
A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndromePerrine Soret, Doreen Belz, Christelle Le Dantec et al.|Nature Communications|2021Cited by 166
Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II studyJulie Ducreux, Bernard Lauwerys, Frédéric Houssiau et al.|Lara D. Veeken|2016Cited by 84